Dawson James Reiterates Dare Bioscience (DARE) at Buy, Assumes DARE-BV1 Can be Commercialized in 2022
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Buy rating and $3.00 price target on Dare Bioscience (NASDAQ: DARE). The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
